Design and synthesis of novel conformationally restricted HIV protease inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 24, 1998, Pages 3637-3642

  Salituro, Francesco G ^a   Baker, Christopher T ^a   Court, John J ^a   Deininger, David D ^a   Kim, Eunice E ^a   Li, Biquin ^a   Novak, Perry M ^a   Rao, Bhisetti G ^a   Pazhanisamy, S ^a   Porter, Margaret D ^a   Schairer, Wayne C ^a   Tung, Roger D ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; PROTEINASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; CYCLIZATION; DRUG CONFORMATION; DRUG DESIGN; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANTI-HIV AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032535314     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00670-2     Document Type: Article

References (13)

1. 1. Baker, C. T.; Salituro, F. G.; Court, J. J.; Deininger, D. D.; Kim, E. E.; Li, B.; Novak, P. M.; Rao, B. G.; Pazhanisamy, S.; Schairer, W. C.; Tung, R. D. Bioorg. Med. Chem. Lett. 1998, 8, proceeding paper.
2. 2. (a) Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. J. Am. Chem. Soc. 1995, 117 1181.
3. (b) Navia, M. A.; Sato, V. L.; Tung, R. D. International Antiviral News 1995, 3, 143.
4. (c) Partaledis, J. A.; Yamaguchi, K.; Tisdale, M.; Blair, E. E.; Falcione, C.; Maschera, B.; Myers, R. E.; Pazhanisamy, S.; Futer, O.; Cullinan, A. B.; Stuver, C. M.; Byrn, R. A.; Livingston, D. J. J. Virol. 1995, 69, 5228.
5. (d) Rao, B. G.; Dwyer, M. D.; Thomson, J. A.; Baker, C. T.; Deininger, D. D.; Murcko, M. A.; Tung, R. D.; Navia, M. A.; Kim, E. E. Antiviral Ther. 1996, 1, 13.
6. (e) Painter, G. R.; Ching, S.; Reynolds, D.; St. Clair, M.; Sadler, B. M.; Elkins, M.; Blum, R.; Dornsife, R.; Livingston, D. J.; Partaledis, J. A.; Pazhanisamy, S.; Tung, R. D.; Tisdale, M. Drugs Fut. 1996, 21, 347.
7. 3. (a) March, D. R.; Fairlie, D. P. In Designing New Antiviral Drugs for AIDS: HIV-1 Protease and Its Inhibitors; R. G. Landes Company: Austin, 1996.
8. (b) Chrusciel, R. A.; Romines, K. R.; Exp. Opin. Ther. Pat. 1997, 7, 111.
9. (c) Vacca, J.P.; Condra, J.H. Drug Disc Today 1997, 2, 261.
10. (d) Flexner, C. N. Engl. J. Med. 1998, 338, 1281.
11. 4. The synthesis of compound 3 and its diasteriomers followed the general procedures outlined in Schemes 1-4 utilizing the commercially available enantiomers of 5-benzyl-oxazolidinone.
12. 5. Wei, Z. Y.; Knaus, E. E. Tetrahedron Lett. 1993, 34, 4439.
13. i R isomer selectivity include: Compound 3 (S/R > 10), compound 6 (S/R > 20), compound 5b (S/R > 30).